Literature DB >> 862652

Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup.

S G Dahl, R E Strandjord, S Sigfusson.   

Abstract

Plasma levels of levomepromazine and its sulphoxide were measured in 8 psychiatric patients after repeated doses of levomepromazine tablets or syrup. The rate and extent of absorption of the drug were similar for the two dosage forms, although the extent of presystemic metabolism appeared to be slightly greater after administration of syrup than of tablets. The biological half-life of levomepromazine ranged from 16.5 h to 77.8 h, and a 13-fold variation was seen in the ratio of the total clearance to the absorbed fraction of the dose (Cl/Fpo). It is postulated that individual variation in the dose required for therapy was due in part to individual variation in the pharmacokinetics of the drug.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862652     DOI: 10.1007/bf00607681

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Pharmacokinetics of methotrimeprazine after single and multiple doses.

Authors:  S G Dahl
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

2.  Serum levels of thioridazine in psychiatric patients and healthy volunteers.

Authors:  E Mårtensson; B E Roos
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

3.  Concept of a volume of distribution and possible errors in evaluation of this parameter.

Authors:  S Riegelman; J Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

4.  Studies of delayed-action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine.

Authors:  L E Hollister; S H Curry; J E Derr; S L Kanter
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

5.  [Therapeutic effect and plasma level of thioridazine in schizophrenic patients (author's transl)].

Authors:  H E Klein; O Chandra; N Matussek
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1975-05

6.  Effects of levomepromazine, chlorpromazine and their sulfoxides on isolated rat atria.

Authors:  S Dahl; H Refsum
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

7.  GLC determination of methotrimeprazine and its sulfoxide in plasma.

Authors:  S G Dahl; S Jacobsen
Journal:  J Pharm Sci       Date:  1976-09       Impact factor: 3.534

  7 in total
  6 in total

1.  Region specific distribution of levomepromazine in the human brain.

Authors:  J Kornhuber; H Weigmann; J Röhrich; J Wiltfang; S Bleich; I Meineke; R Zöchling; S Härtter; P Riederer; C Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

2.  Single-dose kinetics of the neuroleptic drug perazine in psychotic patients.

Authors:  U Breyer-Pfaff; K Nill; H W Schied; H J Gaertner; H Giedke
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.

Authors:  Johannes Kornhuber; Jens Wiltfang; Peter Riederer; Stefan Bleich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

Review 4.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat.

Authors:  S G Dahl; H Hall
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Structural changes by sulfoxidation of phenothiazine drugs.

Authors:  S G Dahl; P A Kollman; S N Rao; U C Singh
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.